Engineered immune cells take on tough leukemia in early trial

NCT ID NCT07668557

Recruiting now Disease control Sponsor: iCell Gene Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cells, and infusing them back after a short chemotherapy course. The main goals are to check safety and see if the treatment can shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICG415 CAR-T cells (engineered immune cells targeting CD33 and CLL1 proteins on leukemia cells)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. CAR-T therapy can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

Jiangxi Provincial People's Hospital (Participating Site)
RECRUITING

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Nanchang University (Lead Site)
RECRUITING

Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.